Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00837993 · ClinicalTrials.gov registry record
Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 241
- Enrollment target
NCT00837993: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00837993 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 241 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00837993 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 241 participants
- Enrollment target
Study Summary
Primary Objective: * To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system. Secondary Objective: * To determine the overall and progression-free survival of patients with serous carcinoma of the ovary treated on GOG protocol 158 when reclassified according to tumor grade (low vs. high). Tertiary Objective: * To correlate histologic grade with other prognostic factors.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 241 participants |
| Start Date | 2007-08 |
| Est. Completion | 2012-12 |
What the finished NCT00837993 record still lists
NCT00837993 is an observational study that tracks outcomes without assigning an intervention. The registered 241 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00837993 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00837993 about?
NCT00837993 is a clinical study titled "Ancillary Study GOG 158: Survival Analysis Based on Reclassification to a Two-Tier Grading System". Primary Objective: * To reclassify the histologic grade of the serous ovarian cancer specimens of patients enrolled on Gynecologic Oncology Group (GOG) protocol 158 using a two-tier system. Secondary Objective: * To determine the overall and progression-free survival of patients with serous carci...
What is the current status of trial NCT00837993?
This trial is currently completed. The enrollment target is 241 participants. The study started on 2007-08. Estimated completion is 2012-12.
Who is sponsoring clinical trial NCT00837993?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01189786 · 241 participants · NA
Ex Vivo T-Cell Depletion of Mobilized Peripheral Blood Stem Cells Via CD34-Selection
- NCT05050383 · 241 participants · NA
DISE: Phenotyping Obstruction Patterns
- NCT05683418 · 241 participants · Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors
- NCT07213791 · 241 participants · Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia